SCHEMBL13039997

SCHEMBL13039997

CC[C@H]1OC(C)[C@H](O)[C@@H]1OP

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18868622 0.84 AMY1A (0.38) —
SCHEMBL11890814 0.82 OGA (0.31) —
SCHEMBL13780864 0.79 — —
SCHEMBL24709749 0.76 — —
SCHEMBL14008603 0.76 FUCA1 (0.32) —
SCHEMBL16978265 0.73 FUCA1 (0.39) —
SCHEMBL22330650 0.73 FUCA1 (0.39) —
SCHEMBL25909575 0.73 FUCA1 (0.39) —
SCHEMBL14515183 0.72 — —
SCHEMBL14450140 0.72 FUCA1 (0.42) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7824851-B2 With purine or pyrimidine base; for use in combination with drugs that induce mutation in Flaviviridae at location other than mutation of nucleotide that results in change from serine to a different amino acid in highly conserved consensus sequence XRXSGXXXT of domain B of the RNA polymerase region IDENIX PHARMACEUTICALS, INC. (US) 2010-11-02 — — US disclosed
Send feedback